Results 181 to 190 of about 34,148 (221)
Some of the next articles are maybe not open access.
The Lancet Infectious Diseases, 2012
We believe Helen Cox and colleagues’ proposal to restrict moxifl oxacin use to multidrug-resistant tuberculosis is based on fl awed logic. In a clinical trial of the present fi rst-line regimen for drug-susceptible tuberculosis, cure rates were greater than 95% and no new regimen is likely to improve on this rate.
Carl, Mendel, Martin, Springsklee
openaire +4 more sources
We believe Helen Cox and colleagues’ proposal to restrict moxifl oxacin use to multidrug-resistant tuberculosis is based on fl awed logic. In a clinical trial of the present fi rst-line regimen for drug-susceptible tuberculosis, cure rates were greater than 95% and no new regimen is likely to improve on this rate.
Carl, Mendel, Martin, Springsklee
openaire +4 more sources
Drugs, 1999
Moxilloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing gram-negative and gram-positive bacteria. It has improved activity against gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin.
J A, Balfour, L R, Wiseman
openaire +2 more sources
Moxilloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing gram-negative and gram-positive bacteria. It has improved activity against gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin.
J A, Balfour, L R, Wiseman
openaire +2 more sources
The microbiology of moxifloxacin
Drugs of Today, 2000Moxifloxacin is a new group IV 8-methoxyquinolone. It is slightly less active than ciprofloxacin against enterobacteria and much less effective against P. aeruginosa. However, moxifloxacin is clearly better than ciprofloxacin in treating atypical microorganisms and especially anaerobic bacteria and aerobic Gram-positive cocci, including methicillin ...
J A, García-Rodríguez +1 more
openaire +2 more sources
2014
A comprehensive profile of moxifloxacin HCl with 198 references is reported. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for moxifloxacin HCl, its intermediates, and derivatives are fully described.
Mahmoud M H, Al Omari +3 more
openaire +2 more sources
A comprehensive profile of moxifloxacin HCl with 198 references is reported. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for moxifloxacin HCl, its intermediates, and derivatives are fully described.
Mahmoud M H, Al Omari +3 more
openaire +2 more sources